3.76

3.58% +0.13

After Hours: 3.67 -0.09 -2.39%

AbCellera Biologics Inc (ABCL)

Overview News Price History Option Chain Why ABCL Down? Discussions Forecast

AbCellera Biologics Inc stock is currently priced at $3.76, with a 24-hour trading volume of 1.37M. It has seen a +3.58% increased in the last 24 hours and a -12.35% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.71 pivot point. If it approaches the $3.80 resistance level, significant changes may occur.

Previous Close:

$3.63

Open:

$3.69

24h Volume:

1.37M

Market Cap:

$1.10B

Revenue:

$38.03M

Net Income/Loss:

$-146.40M

P/E Ratio:

-8.3556

EPS:

-0.45

Net Cash Flow:

$-121.38M

1W Performance:

-2.84%

1M Performance:

-12.35%

6M Performance:

-9.18%

1Y Performance:

-44.21%

1D Range:

$3.64

$3.80

52W Range:

$3.62

$8.05

AbCellera Biologics Inc Stock (ABCL) Company Profile

Name

AbCellera Biologics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

604 559 9005

Address

2215 Yukon Street, Vancouver

Employee

174

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

ABCL's Discussions on Twitter

AbCellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy
Nov-16-22	Initiated	Truist	Buy
Dec-21-21	Initiated	The Benchmark Company	Buy
Nov-19-21	Initiated	Piper Sandler	Overweight
Jan-05-21	Initiated	BMO Capital Markets	Outperform
Jan-05-21	Initiated	Berenberg	Buy
Jan-05-21	Initiated	Credit Suisse	Outperform
Jan-05-21	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	Stifel	Buy

View All

AbCellera Biologics Inc Stock (ABCL) Latest News

AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

The Motley Fool

AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

AbCellera Biologics Inc Stock (ABCL) Financials Data

AbCellera Biologics Inc (ABCL) Revenue 2024

ABCL reported a revenue (TTM) of $38.03 million for the quarter ending December 31, 2023, a -92.17% decline year-over-year.

AbCellera Biologics Inc (ABCL) Net Income 2024

ABCL net income (TTM) was -$146.40 million for the quarter ending December 31, 2023, a -192.35% decrease year-over-year.

AbCellera Biologics Inc (ABCL) Cash Flow 2024

ABCL recorded a free cash flow (TTM) of -$121.38 million for the quarter ending December 31, 2023, a -159.30% decrease year-over-year.

AbCellera Biologics Inc (ABCL) Earnings per Share 2024

ABCL earnings per share (TTM) was -$0.52 for the quarter ending December 31, 2023, a -204.00% decline year-over-year.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.